Primaa

The founding team combines deep medical, technical, and business expertise. Fanny Sockeel, the CEO, transitioned from a 12-year career in strategy and management consulting for financial institutions to entrepreneurship. Chief Scientific Officer, Stéphane Sockeel, leverages his background in neuro-imaging, holding a doctorate in neuroscience and a degree in computer vision, to lead the development of the company's deep learning models. The initial idea came from Chief Medical Officer Marie Sockeel, a surgical pathologist who envisioned using AI to automate repetitive tasks and enhance her daily diagnostic workflow.

Primaa develops software that assists pathologists by analyzing digitized tissue slides to provide rapid and reliable initial diagnoses, a process traditionally done manually. The company's business model targets hospitals, pathology laboratories, and pharmaceutical companies. By digitizing slides and creating a vast image database with medical partners, Primaa's AI can identify various pathologies. This approach is designed to improve diagnostic precision, save pathologists time, and accelerate case reviews. The technology integrates into existing laboratory workflows and digital pathology viewers, acting as a companion tool for physicians.

The company's product line includes CE-marked solutions like Cleo Breast and Cleo Skin. Cleo Breast is an AI-powered tool for detecting critical biomarkers in breast cancer cases, such as invasive carcinoma, metastases, and mitosis. Cleo Skin aids in the analysis of skin biopsies by identifying key biomarkers for lesions and providing measurements. In March 2025, Primaa announced a partnership with Gestalt to integrate its skin cancer algorithms into Gestalt's PathFlow digital pathology platform. The company has successfully raised $7.58 million over three funding rounds, with its latest Series A round in November 2024 securing $5.38 million. This capital is intended to fuel development and international commercialization.